- Stocks
- Healthcare
- NYSEAMERICAN: OCX

Price (delayed)

$3.19

Market cap

$42.65M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4,591.01

Enterprise value

$35.36M

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical

The company's EPS rose by 47% YoY and by 47% QoQ

OncoCyte's net income has increased by 40% YoY and by 9% QoQ

OncoCyte's equity has surged by 96% QoQ but it has decreased by 48% YoY

OCX's quick ratio has surged by 72% since the previous quarter but it is down by 45% year-on-year

OncoCyte's gross profit has shrunk by 73% QoQ

OCX's gross margin has dropped by 63% since the previous quarter

What are the main financial stats of OCX

Market
Valuations
Earnings

Shares outstanding

13.37M

Market cap

$42.65M

Enterprise value

$35.36M

Price to earnings (P/E)

N/A

Price to book (P/B)

1.88

Price to sales (P/S)

40.13

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

34.56

Revenue

$1.02M

EBIT

-$36.28M

EBITDA

-$34.87M

Free cash flow

-$16.89M

Per share
Balance sheet
Liquidity

EPS

-$4,591.01

Free cash flow per share

-$1.31

Book value per share

$1.7

Revenue per share

$0.08

TBVPS

$1.41

Total assets

$74.72M

Total liabilities

$52.02M

Debt

$3.67M

Equity

$22.7M

Working capital

$2.77M

Debt to equity

0.16

Current ratio

1.38

Quick ratio

1.53

Net debt/EBITDA

0.21

Margins
Efficiency
Dividend

EBITDA margin

-3,408.4%

Gross margin

8.1%

Net margin

-3,552.9%

Operating margin

-3,576.8%

Return on assets

-48.6%

Return on equity

-159.2%

Return on invested capital

-1,101.1%

Return on capital employed

-53.7%

Return on sales

-3,546.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the OncoCyte stock price performed over time

Intraday

4.59%

1 week

1.59%

1 month

4.59%

1 year

-5.34%

YTD

27.6%

QTD

8.14%

How have OncoCyte's revenue and profit performed over time

Revenue

$1.02M

Gross profit

$83,000

Operating income

-$36.59M

Net income

-$36.35M

Gross margin

8.1%

Net margin

-3,552.9%

The operating margin has shrunk by 149% YoY and by 23% QoQ

The operating income has dropped by 132% year-on-year but it has grown by 9% since the previous quarter

OncoCyte's gross profit has shrunk by 73% QoQ

OCX's gross margin has dropped by 63% since the previous quarter

What is OncoCyte's growth rate over time

What is OncoCyte stock price valuation

P/E

N/A

P/B

1.88

P/S

40.13

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

34.56

The company's EPS rose by 47% YoY and by 47% QoQ

OncoCyte's equity has surged by 96% QoQ but it has decreased by 48% YoY

The stock's price to book (P/B) is 34% more than its last 4 quarters average of 1.4 but 28% less than its 5-year quarterly average of 2.6

The price to sales (P/S) is 94% less than the 5-year quarterly average of 701.5 but 89% more than the last 4 quarters average of 21.2

The revenue has decreased by 26% QoQ and by 7% YoY

How efficient is OncoCyte business performance

The company's return on sales rose by 35% YoY but it fell by 22% QoQ

OCX's ROIC is down by 34% year-on-year and by 15% since the previous quarter

The company's return on equity fell by 26% YoY and by 11% QoQ

OCX's return on assets is up by 14% year-on-year and by 6% since the previous quarter

What is OCX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for OCX.

How did OncoCyte financials performed over time

OCX's total assets is 44% greater than its total liabilities

The current ratio has soared by 77% from the previous quarter but it has contracted by 50% YoY

OCX's quick ratio has surged by 72% since the previous quarter but it is down by 45% year-on-year

OCX's debt is 84% smaller than its equity

The debt to equity has surged by 129% year-on-year but it has declined by 45% since the previous quarter

OncoCyte's equity has surged by 96% QoQ but it has decreased by 48% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.